Get the Stockscreener App
12.17
4.85%
-0.62
After Hours:
12.18
0.010
+0.08%
CorMedix Inc stock is traded at $12.17, with a volume of 1.72M.
It is down -4.85% in the last 24 hours and up +42.51% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$12.79
Open:
$12.79
24h Volume:
1.72M
Relative Volume:
1.37
Market Cap:
$738.44M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-13.23
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
+8.76%
1M Performance:
+42.51%
6M Performance:
+150.93%
1Y Performance:
+263.28%
1-Day Range:
$12.14
$13.09
1-Week Range:
$10.85
$13.09
52-Week Range:
$2.89
$13.85
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.17 | 738.44M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
Boral Capital sets CorMedix stock target, Buy rating on potential By Investing.com - Investing.com Australia
Boral Capital sets CorMedix stock target, Buy rating on potential - Investing.com
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates - Yahoo Finance
CorMedix soars on Q4 preliminary results, business updates - MSN
CorMedix stock soars on preliminary Q4 revenue beat - Investing.com India
CorMedix Soars 32% on Upbeat Q4 Forecast - Wall Street Pit
CorMedix Shares Rise 21% After Preliminary 4Q Results Beat Estimates - MarketWatch
CorMedix: Finally In Commercialization Mode (NASDAQ:CRMD) - Seeking Alpha
CorMedix soars on Q4 preliminary resyults, business updates - MSN
CorMedix stock soars on preliminary Q4 revenue beat By Investing.com - Investing.com Canada
CRMDCorMedix Inc. Latest Stock News & Market Updates - StockTitan
CorMedix soars on Q4 preliminary results, business updates (CRMD:NASDAQ) - Seeking Alpha
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update - The Manila Times
CorMedix Hits Breakeven Target with $31M Q4 Revenue, Secures $25M in New Orders for DefenCath - StockTitan
Where are the Opportunities in (CRMD) - Stock Traders Daily
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year? - MSN
CorMedix price target raised to $12 from $11 at RBC Capital - Yahoo Finance
RBC optimistic on CorMedix shares as DefenCath launch gains traction in outpatient - Investing.com India
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans - Investing.com Australia
CorMedix Inc. Added to Nasdaq Biotechnology Index - The Manila Times
CorMedix joins Nasdaq Biotechnology Index - Investing.com
CorMedix joins Nasdaq Biotechnology Index By Investing.com - Investing.com UK
CorMedix (CRMD) Earns Coveted Spot in Nasdaq Biotechnology Index in December Update - StockTitan
Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Insider Monkey
CorMedix's SWOT analysis: defencath launch propels stock amid expansion By Investing.com - Investing.com Nigeria
CorMedix's SWOT analysis: defencath launch propels stock amid expansion - Investing.com India
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark - Simply Wall St
CorMedix's SWOT analysis: defencath launch boosts stock outlook By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock outlook - Investing.com
Closed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMR - GlobeNewswire Inc.
When (CRMD) Moves Investors should Listen - Stock Traders Daily
CorMedix Inc. Announces FDA IND Filing for Neutrolin(R) in United States - Marketscreener.com
CorMedix supports CMS policy updates - TipRanks
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products - The Manila Times
CorMedix: Major CMS Policy Change to Boost DefenCath Access for 30% of Dialysis Patients | CRMD Stock News - StockTitan
CorMedix Approves Key Governance and Incentive Changes - TipRanks
Cormedix EVP Elizabeth Hurlburt sells $1.57m in stock - Investing.com India
When the Price of (CRMD) Talks, People Listen - Stock Traders Daily
Nomura Holdings Inc's Strategic Reduction in CorMedix Inc Shares - GuruFocus.com
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):